Filing Details
- Accession Number:
- 0001209191-22-002849
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-11 16:10:25
- Reporting Period:
- 2022-01-10
- Accepted Time:
- 2022-01-11 16:10:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1549595 | Nurix Therapeutics Inc. | NRIX | Pharmaceutical Preparations (2834) | 270838048 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1817199 | Christine Ring | C/O Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco CA 94158 | General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-01-10 | 1,200 | $1.86 | 2,486 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-01-10 | 1,200 | $27.14 | 1,286 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2022-01-10 | 1,200 | $0.00 | 1,200 | $1.86 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
100,066 | 2029-09-30 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.